Le Lézard
Classified in: Health
Subject: RCL

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL due to Potential Bacillus cereus Contamination in the Product

Company Contact: Inmar Return Services
Name: Inmar Customer Service - Recalls
Phone Number: 1-877-597-0878
Email: rxrecalls@inmar.com 

PISCATAWAY, N.J., March 14, 2023 /PRNewswire/ -- Camber Pharmaceuticals, Inc. is voluntarily recalling lot # E220182 of Atovaquone Oral Suspension, USP 750mg/5mL to the Consumer/User level, due to the potential Bacillus cereus contamination in the product.

Risk Statement: In the population most at risk, immunocompromised population, there is a reasonable probability that microbial contamination of Atovaquone Oral Suspension can result in disseminated, life threatening infections such as endocarditis and necrotizing soft tissue infections.  To date, Camber has not received any reports of adverse events related to this recall.  

Atovaquone Oral Suspension, USP is indicated for prevention and treatment of Pneumocystis jiroveci pneumonia (PCP) in adults and children 13 years of age and older who cannot tolerate other medicines, such as trimethoprim-sulfamethoxazole.

Atovaquone Oral Suspension, USP was distributed Nationwide to Wholesalers, Distributors, Retail Pharmacies, and Mail Order Pharmacies.

The product is packaged in 210mL HDPE bottle in a mono carton.  The identified NDC # associated with the product is 31722-629-21, UPC # 331722629218, and the affected lot# is E220182 with an expiration date of 12/2023.

Camber Pharmaceuticals, Inc. is notifying its distributors and customers by our Reverse Logistics Company, Inmar, by mailings and emails communications method and is arranging for returns of all recalled Atovaquone Oral Suspension, USP.

Consumers/distributors/retailers that have product which is being recalled should stop using/return to place of purchase/discard/contact their doctor, etc.

Consumers with questions regarding this recall can contact Inmar by phone at 1-877-597-0878 or email rxrecalls@inmar.com, Monday ? Friday, 9am ? 5pm Eastern Time. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

SOURCE Camber Pharmaceuticals

These press releases may also interest you

at 13:05
Bone Biologics Corporation , a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effective on June 5, 2023 and that its common stock and warrants will begin trading on a split-adjusted...

at 13:02
PathomIQ INC. and Neuberg Diagnostics, today announced a multi-year partnership to accelerate clinical deployment of PATHOMIQ's AI based prognostic and predictive biomarkers as a Lab Developed Test (LDT) which will be available in Neuberg...

at 13:00
Trellis Company has released its annual Student Financial Wellness Survey, shedding light on the financial challenges faced by students and their perceptions regarding the value of a college education. The survey, conducted in the fall of 2022,...

at 13:00
The utilization of digital twins in the healthcare industry is expected to revolutionize patient care and enhance overall healthcare outcomes in the near future. A digital twin refers to a virtual replica of a physical entity, such as a human body or...

at 13:00
Octapharma to present new clinical and scientific findings for wilate®, Nuwiq®, octaplex® and atenativ® at the upcoming ISTH 2023 CongressNew data and clinical study developments will be presented in nine posters and during two Supported SymposiaThe...

at 13:00
Eleven major neuroscientific research projects related...

News published on and distributed by: